Eslicarbazepine acetate: a well-kept secret?
作者信息
Ben-Menachem Elinor
出版信息
Epilepsy Curr. 2010 Jan;10(1):7-8. doi: 10.1111/j.1535-7511.2009.01337.x.
Abstract
摘要
相似文献
1
Eslicarbazepine acetate: a well-kept secret?
Epilepsy Curr. 2010 Jan;10(1):7-8. doi: 10.1111/j.1535-7511.2009.01337.x.
2
Eslicarbazepine acetate.
CNS Drugs. 2009;23(1):71-9. doi: 10.2165/0023210-200923010-00005.
3
Disposition of eslicarbazepine acetate in the mouse after oral administration.
Fundam Clin Pharmacol. 2008 Oct;22(5):529-36. doi: 10.1111/j.1472-8206.2008.00617.x. Epub 2008 Aug 15.
4
Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.
Brain. 2015 Feb;138(Pt 2):371-87. doi: 10.1093/brain/awu339. Epub 2014 Dec 2.
5
Aptiom (eslicarbazepine acetate) as a dual inhibitor of β-secretase and voltage-gated sodium channel: advancement in Alzheimer's disease-epilepsy linkage via an enzoinformatics study.
CNS Neurol Disord Drug Targets. 2014;13(7):1258-62. doi: 10.2174/1871527313666140917121600.
6
Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.
Drug Saf. 2017 Dec;40(12):1231-1240. doi: 10.1007/s40264-017-0576-4.
7
Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Epilepsia. 2018 Feb;59(2):479-491. doi: 10.1111/epi.13993. Epub 2018 Jan 25.
8
Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis.
CNS Drugs. 2018 Mar;32(3):189-196. doi: 10.1007/s40263-018-0504-x.
9
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
Int J Pharm Compd. 2018 Sep-Oct;22(5):433-439.
10
Eslicarbazepine acetate: an update on efficacy and safety in epilepsy.
Epilepsy Res. 2014 Jan;108(1):1-10. doi: 10.1016/j.eplepsyres.2013.10.005. Epub 2013 Oct 23.
引用本文的文献
1
The potential of dibenzazepine carboxamides in cancer therapy.
Front Pharmacol. 2025 Mar 28;16:1564911. doi: 10.3389/fphar.2025.1564911. eCollection 2025.
2
Eslicarbazepine induces apoptosis and cell cycle arrest in C6 glioma cells in vitro and suppresses tumor growth in an intracranial rat model.
BMC Cancer. 2024 Sep 4;24(1):1099. doi: 10.1186/s12885-024-12840-3.
3
Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products.
Pharmaceutics. 2020 Oct 29;12(11):1031. doi: 10.3390/pharmaceutics12111031.
4
The expanding role of prodrugs in contemporary drug design and development.
Nat Rev Drug Discov. 2018 Aug;17(8):559-587. doi: 10.1038/nrd.2018.46. Epub 2018 Apr 27.
5
The Prodrug Approach: A Successful Tool for Improving Drug Solubility.
Molecules. 2015 Dec 29;21(1):42. doi: 10.3390/molecules21010042.
6
A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy.
J Cent Nerv Syst Dis. 2011 Jul 20;3:179-87. doi: 10.4137/JCNSD.S4888. Print 2011.
7
Update on treatment of partial onset epilepsy: role of eslicarbazepine.
Neuropsychiatr Dis Treat. 2010 Nov 2;6:723-30. doi: 10.2147/NDT.S5840.
8
[Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate].
Nervenarzt. 2011 Jun;82(6):764-7. doi: 10.1007/s00115-010-3177-3.
本文引用的文献
1
Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Epilepsia. 2009 Mar;50(3):454-63. doi: 10.1111/j.1528-1167.2008.01946.x. Epub 2009 Feb 21.
2
Eslicarbazepine acetate.
CNS Drugs. 2009;23(1):71-9. doi: 10.2165/0023210-200923010-00005.
3
Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Funct Neurol. 2008 Apr-Jun;23(2):97-100.
4
Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment.
Eur J Clin Pharmacol. 2008 Mar;64(3):267-73. doi: 10.1007/s00228-007-0414-1. Epub 2007 Dec 21.
5
The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.
Lancet. 2007 Mar 24;369(9566):1000-15. doi: 10.1016/S0140-6736(07)60460-7.
6
Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures.
Epilepsia. 2007 Mar;48(3):497-504. doi: 10.1111/j.1528-1167.2007.00984.x. Epub 2007 Feb 21.
7
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.
Epilepsia. 2006 Jul;47(7):1094-120. doi: 10.1111/j.1528-1167.2006.00585.x.
8
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
J Med Chem. 1999 Jul 15;42(14):2582-7. doi: 10.1021/jm980627g.
Zotero 插件